Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Karl-Johan Malmberg Clear advanced filters

  • Variation in HLA class I signal peptides sets the strength of NKG2A-mediated education of CD56bright natural killer (NK) cells, revealing a genetically encoded ‘set point’ for innate immune fitness and linking NK cell tuning to protection from cancer and inflammatory disease.

    • Pilar Maria Lanuza
    • Karl-Johan Malmberg
    News & Views
    Nature Immunology
    Volume: 27, P: 645-646

  • Natural killer cells were so named because of their ability to lyse tumour cells. Although initial studies have provided encouraging results, several challenges remain in optimizing the use of NK cells in therapeutic settings, as is described in this Review.

    • Hans-Gustaf Ljunggren
    • Karl-Johan Malmberg
    Reviews
    Nature Reviews Immunology
    Volume: 7, P: 329-339

  • New findings show that a subpopulation of mucosal RORγt+ cells expresses natural killer cell receptors and produces interleukin 22. These innate immune cells may be pivotal in maintaining mucosal homeostasis.

    • Karl-Johan Malmberg
    • Hans-Gustaf Ljunggren
    News & Views
    Nature Immunology
    Volume: 10, P: 11-12

  • A promising phase 1 trial with patients with refractory Hodgkin lymphoma underscores the potential value of allogeneic natural killer (NK) cell therapy guided by NK cell-specific engagers.

    • Ebba Sohlberg
    • Karl-Johan Malmberg
    News & Views
    Nature Medicine
    Volume: 31, P: 1755-1756

  • Natural killer (NK) cells are functionally calibrated against self MHC during a process termed education. Here the authors show that NK cell education is associated with the accumulation of dense-core secretory lysosomes for expedited release of granzyme B and Ca2+ flux upon target recognition and NK cell activation.

    • Jodie P. Goodridge
    • Benedikt Jacobs
    • Karl-Johan Malmberg
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-15

  • The use of chimeric antigen receptor modified immune cell therapeutics has improved the treatment of a range of tumours. Here the authors explore a dual-target iPSC-derived NK cell product as a potential therapeutic for the treatment of multiple myeloma.

    • Frank Cichocki
    • Ryan Bjordahl
    • Jeffrey S. Miller
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-15

  • γδ T cells are unique T lymphocytes with cytotoxic functions, targeting infections and tumours. Here authors show that the target killing function of γδ T cells is tightly regulated at the level of the availability of lytic molecules granzyme B and perforin.

    • Patrick A. Sandoz
    • Kyra Kuhnigk
    • Björn Önfelt
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-16

  • Single-cell technologies have unveiled a complex understanding of NK cells that has led to variations in nomenclature and inconsistencies across the scientific literature. Here, Vivier and colleagues used these technologies to dissect the heterogeneity of NK cells, revealing three prominent NK cell subsets in healthy human blood.

    • Lucas Rebuffet
    • Janine E. Melsen
    • Eric Vivier
    ResearchOpen Access
    Nature Immunology
    Volume: 25, P: 1474-1488

  • Genome editing approaches can be used to confer immune-evasive properties to allogeneic cellular immunotherapies, with the aim of achieving persistent responses and efficiencies that are comparable to those of autologous chimeric antigen receptor T cell therapies. This Perspective discusses how current knowledge about viral or tumour immune evasion could be incorporated into the design of off-the-shelf tumour-specific T and NK cells for the production of cost-effective and scalable cancer immunotherapies.

    • Karen E. Martin
    • Quirin Hammer
    • Karl-Johan Malmberg
    Reviews
    Nature Reviews Immunology
    Volume: 24, P: 680-693